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Controlled production of the elusive metastable
form II of acetaminophen (paracetamol): a fully
scalable templating approach in a cooling
environment†
Lauren R. Agnew,ab Dyanne L. Cruickshank,c Thomas McGloned and
Chick C. Wilson*ab
A scalable, transferable, cooling crystallisation route to the elusive,
metastable, form II of the API acetaminophen (paracetamol) has
been developed using a multicomponent ‘‘templating’’ approach,
delivering 100% polymorphic phase pure form II at scales up to
120 g. Favourable solubility and stability properties are found for
the form II samples.
Enhancing physiochemical properties of active pharmaceutical
ingredients (APIs) has been widely researched in recent years to
aid in the downstream processing of many pharmaceuticals.
For example, increased aqueous solubility results in higher
bioavailability, the ability to engineer layered structures can
result in improved compaction properties, and modifying the
stability of APIs can be of critical importance in transportation
and storage. Such property enhancement can be achieved both
in polymorphic forms of the API, and in multicomponent
molecular complexes containing the API (e.g. co-crystals). There
have been numerous reports on the use of multicomponent
crystallisation procedures, in particular co-crystallisation, to
achieve such physical property enhancement.1–5However, there
are very limited reports targeting different polymorphic forms
of single component APIs using a multicomponent approach.
A range of API molecules have been shown to be polymorphic on
crystallisation into the solid state; containing only the desired
API, these polymorphs can display markedly different physical
properties. Many of these polymorphic forms can be elusive
and accessible under specialised conditions or in low yields,
which hampers the potential to manufacture and utilise them in
pharmaceutical products. Of relevance to the work presented here,
a number of elusive, metastable polymorphic forms have been
discovered serendipitously through attempted co-crystallisation
experiments.6–8 Systems such as these have introduced the idea
of using a secondmolecular component, termed here a templating
molecule, in the crystallisation process to isolate and convert a
previously stable polymorphic form of the target API to a new and
often elusive metastable form, while not being present itself in the
final product. Crucially, this has previously rarely been achieved by
design and in this work such a designed process is not only
achieved, but scaled to produce large quantities of an elusive
polymorph with enhanced physical properties.
Acetaminophen (paracetamol; PCM) is a widely used analgesic
and antipyretic which has been studied extensively in the solid
state.9–12 It exists in five polymorphic forms (of which two can
only be accessed at high pressure), two of which have relevance in
this work (Fig. 1). Form I displays a herringbone arrangement of
molecules within the crystal structure, whilst form II is layered.
This layering gives form II the enhanced physical properties of
increased solubility (assisting bioavailability) and compressibility
upon tableting (assisting processing). Previous routes to obtaining
metastable form II include reaction coupling,13 swift cooling,14
enforcing Ostwald’s rule of stages,15 use of polymer additives,16
heterogeneous nucleation17 and multicomponent templating
approaches.18 The last of these has shown the possibility to template
form II with a variety of benzoic acid (BA) derivatives. However, this
was only achieved in an evaporative crystallisation environment.18
Fig. 1 PCM-I (left) and PCM-II (right).
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The present work looks at the production of metastable form II,
with 4-halobenzoic acid derivatives (4-bromobenzoic acid (4-BrBA),
4-chlorobenzoic acid (4-ClBA), 4-fluorobenzoic acid (4-FBA)) as
templating molecules, in a cooling crystallisation environment.
The 4-substituted benzoic acid derivatives were shown to produce
form II most reliably in evaporative studies and so were chosen
as initial additives. Here, we develop this designed approach
by also using the structurally similar molecule metacetamol
(MCM), only previously studied in relation to its effect on PCM-I
morphology,19,20 as a templating molecule for PCM-II pro-
duction. Use of this designed templating approach to access a
range of elusive solid forms in a ‘‘discovery’’ context has also
recently been discussed by Thomas et al. in a complementary
paper in this issue.
Cooling crystallisation is becoming more widely used in
industry, as it oﬀers improved control of the supersaturation
within the system and hence greater control of both poly-
morphic form and particle attributes, with many continuous
manufacturing processes, such as those using the continuous
oscillatory baﬄed crystalliser21 and mixed suspension mixed
product removal platforms,22 employing it. There are a number of
examples in the literature using cooling crystallisation methods
with single component systems but to date obtaining polymorphic
control of a single-molecule API system in a cooling environment
with more than one (non-solvent) molecular component present
has not been achieved. With regard to the PCM system, previous
cooling crystallisation experiments, have shown the reproducible
formation of only PCM-I.23 A solution-mediated phase transition
from form II to form I does, however, occur during cooling,
consistent with Ostwald’s rule of stages.
In this work, the Polar Bear Plus Crystalliser from Cambridge
Reactor Design is used to provide controlled cooling crystal-
lisation conditions, in a systematic study of the production of
PCM-II using a templating approach. 1.5 cm3 vials containing
ca. 250 mg of paracetamol, varying weight percentages of BA
templating molecules (0.4–2% for 4-BrBA and 4-ClBA and 1–4%
for 4-FBA) and 1 g of 60 : 40 v/v H2O : IPA solvent were subjected
to a stepped cooling profile (Fig. 2) from 70 to 5 1C at a rate
of 0.02 1C min1. Solutions were cooled in 5 1C intervals and
subsequently stirred for one hour to reach steady state condi-
tions. Magnetic bottom stirring was used at a rate of either
800 rpm or 400 rpm. The experiments were designed to ensure
that the BA templating molecule remained in solution at the end
of the crystallisation (informed by solubility curves, ESI,† Fig. S1).
A variety of cooling rates were investigated in order to optimise
the crystallisation process, however production of PCM-II with BA
co-former templating molecules was only achieved using the
cooling conditions described above.
For MCM, varying weight percentages (1, 2, 5, 10 and 25%)
as a proportion of ca. 250 mg PCM and 1 g of one of three
solvents (ethanol, IPA or 60 : 40 H2O : IPA) were subjected to
both a stepped cooling profile (Fig. 2) at three diﬀerent cooling
rates: 0.02 1C min1, 0.2 1C min1 and 1 1C min1 and a linear
cooling profile at 1 1C min1; the latter, rapid cooling rate,
was used to mimic the cooling conditions that may be more
relevant to continuous crystallisation. Larger vials (20 ml) and
varying sizes of round bottomed flasks (RBFs) were used to
scale up the production of PCM-II in the presence of MCM once
the optimal cooling conditions had been established.
Powder X-ray diﬀraction (PXRD) confirms the formation of
PCM-II (ESI,† Fig. S2), with no additional peaks corresponding
to the presence of co-former, PCM-I or any other solid form.
Diﬀerential scanning calorimetry (DSC) measurements confirmed
the absence of any templating molecule in lower concentrations
than detectable by PXRD or Raman spectroscopy (ESI,† Fig. S3).
Table 1 highlights the specific conditions used to obtain
PCM-II in a designed, reproducible manner. The production of
PCM-II is highly dependent on crystallisation conditions as well
as the concentrations of both the co-former molecules and
PCM; more recently, design of experiments analysis on the
PCM/MCM system has allowed these eﬀects to be quantified,
enhancing the design element of this study. The concentrations
of the co-former with respect to the solvents were chosen so that
the templating molecule was undersaturated at 5 1C, ensuring it
remains in solution at the completion of the cooling regime. The
higher stirring rates required for 4-BrBA can be attributed to the
fact that these conditions provide the greater mass transfer
required for lower concentrations of 4-BrBA. Investigations into
the scaling potential of the templated crystallisation of PCM-II
with 4-FBA have been largely unsuccessful. It can be suggested
that this is due to poor mass transfer at higher scales and the low
solubility of the co-former molecule.
On the other hand, the use of MCM as a templating molecule
has allowed for the reproducible scale-up to the 10 ml solvent
scale (ca. 2.5 g PCM) at all three cooling rates and all cooling
profiles currently explored. Scaled production of PCM-II using a
rapid cooling rate of 1 1C min1 is a significant step towards
mimicking the conditions that would likely be experienced
in operational continuous crystallisation platforms. Further
scale-up attempts required increasing the concentration of MCM
and truncating the cooling at a final temperature of 20 1C, allowing
the system to be scaled into a 50 ml RBF, yielding large quantities
of410 g of 100% pure PCM-II in single runs. It can be suggested
that the higher concentrations of MCM are needed to account for
the poorer mass transfer experienced through magnetic bottom
Fig. 2 The stepped cooling profile employed, showing the six regions of
dwelling employed to ensure steady state is reached.
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stirring at larger scales. Use of overhead stirring, and the greater
associated mass transfer, has allowed for the further scaling of
the system to volumes as high as 800 ml, with production on the
100 ml scale fully reproducible. Due to the widening of the
metastable zone width with overhead stirring, a greater concen-
tration of PCM was used; a concentration of 300 mg g1 PCM
coupled with 25 wt% MCM reproducibly gives 100% PCM-II.
Currently, all samples of PCM-II produced are stable for periods
of months (ESI,† Fig. S4), further confirming the absence of any
form I, the presence of which would seed the conversion of form
II back to the stable form I. The kinetics of this conversion are
currently under investigation, with initial results showing that
presence of 5 wt% or greater of form I in proportion to form II
results in partial transformation, in the solid state, of the sample
back to form I within a week. The stability of form II established
here is significantly enhanced from that resulting from previously
reported methods of obtaining PCM-II; the use of polymer
additives gave samples that were only stable for five hours.16
It is worth noting that previous evaporative work empha-
sised the need to use stoichiometric ratios of PCM to co-former
molecule to ensure the production of form II; the lower, at times
catalytic, amounts used in this work under cooling conditions
are in stark contrast to this.
A solubility curve for PCM-II has been previously reported,14
however the methodology or literature used to obtain these
data were undisclosed. The aqueous solubility of PCM-II as
determined using turbidimetric methods in a Technobis Crystal 16
device is thus reported here (Fig. 3; and in ESI†), confirming and
quantifying its enhanced solubility.
In summary, a multicomponent templating approach to
paracetamol form II has been established in a cooling crystal-
lisation environment using two templating molecules. Form II
is produced reliably and in 100% polymorphic purity, with a
0.4–4% and 10–40% w/w co-former to PCM concentration for
4-fluorobenzoic acid and metacetamol respectively required
to template this conversion. Metacetamol displays a higher
solubility in the chosen solvent system than 4-fluorobenzoic
acid and so higher concentrations were able to be used, aiding in
the scale-up of the system to 800 ml volume, producing4100 g
PCM-II in a single run. The crystallisation experiment was
designed to ensure the templating co-former remains in solution
thus reducing the need for further separation processes. The use
of cooling crystallisation provides improved control of super-
saturation within the system and is the first key step in transfer
of the process to continuous crystallisation platforms. Although
we have been able to design this templated crystallisation, the
mechanism of this templating process is unknown; however it
can be suggested that the templating co-former affects the
solution-mediated phase transition that normally occurs during
the cooling of PCM in the absence of a co-former molecule.
This initial transfer into a cooling crystallisation environment
provides a key start point for the transfer of this system into
continuous platforms at industrial scale.
This work was supported by the EPSRC CMAC under grants
EP/I033459/1 and EP/K503289/1.
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